Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Holdings Raised by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP raised its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 2.3% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,347,082 shares of the medical equipment provider's stock after purchasing an additional 30,891 shares during the period. Dimensional Fund Advisors LP owned 1.94% of Lantheus worth $120,510,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new position in shares of Lantheus during the 3rd quarter valued at about $25,000. Kestra Investment Management LLC purchased a new stake in shares of Lantheus in the 4th quarter valued at approximately $27,000. Summit Securities Group LLC acquired a new stake in shares of Lantheus during the 4th quarter worth approximately $37,000. UMB Bank n.a. raised its position in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after buying an additional 134 shares during the period. Finally, World Investment Advisors LLC acquired a new position in Lantheus in the third quarter valued at approximately $60,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Analysts Set New Price Targets

Several research firms have issued reports on LNTH. B. Riley cut their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. Truist Financial boosted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Finally, JMP Securities reiterated a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Lantheus has an average rating of "Moderate Buy" and an average price target of $129.43.

Lantheus Trading Up 1.5 %

Shares of Lantheus stock traded up $1.52 during trading hours on Thursday, reaching $105.86. The stock had a trading volume of 602,655 shares, compared to its average volume of 950,149. The firm has a market capitalization of $7.25 billion, a price-to-earnings ratio of 17.63 and a beta of 0.20. Lantheus Holdings, Inc. has a 1 year low of $65.89 and a 1 year high of $126.89. The firm has a 50 day simple moving average of $98.78 and a two-hundred day simple moving average of $95.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Activity at Lantheus

In related news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 63,109 shares of company stock worth $6,016,046. Corporate insiders own 1.50% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.